Ronald Fisher Is Not Being ‘Cancelled’, But His Eugenic Advocacy Should Have Consequences
By Eric Michael Johnson,
This View of Life
| 04. 12. 2021
Photo by Schutz, stained glass designed by Maria McClafferty,
CC BY-SA 2.5, via Wikimedia Commons
While Black Lives Matter protests raged and confederate statues were toppled across the United States following the killing of George Floyd, the quiet removal of a stained-glass window at Cambridge University closed one chapter in the history of scientific racism. On June 26, 2020, a commemorative window in honor of the statistician, geneticist, and evolutionary biologist Ronald Aylmer Fisher was targeted for removal from Gonville and Caius College where he had lived during his time at Cambridge.1 A student petition that had received more than 1,400 signatures objected to Fisher’s “endorsements of colonialism, white supremacy and eugenics.”2 Following a review, the College Council decided to support the students with a statement acknowledging Fisher’s fundamental contributions to statistics and genetics but concluded that honoring him would not constitute a welcoming environment given that he was “a prominent proponent of eugenics, both in his scientific work and his public pronouncements throughout his career.”3 Other organizations, such as the Society for the Study of Evolution...
Related Articles
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Paul Knoepfler, Stat | 06.24.2026
What if you could precisely change the genome of a pre-implantation human embryo and then safely use that embryo to try to generate a healthier person? It’s a wild idea, but one that technology over the past decade has steadily...